Announcement • May 30
ADICON Holdings Limited Announces Yeh Richard as the Lead Independent Non-Executive Director, Effective May 27, 2026 ADICON Holdings Limited announced that Mr. YEH Richard, an independent non-executive Director, had been designated as the lead independent non-executive Director with effect from May 27, 2026. Mr. YEH is currently the chairman of the audit committee and a member of the nomination committee of the Board. The responsibilities of the lead independent non-executive Director are not different from or greater than those of other independent non-executive Directors. Mr. YEH’s primary responsibility as the lead independent non-executive Director is to facilitate and strengthen communication among the independent non-executive Directors, between the independent non-executive Directors and the other members of the Board, and with the shareholders (in particular, the minority shareholders). The position of the lead independent non-executive Director is not an executive position in the Company, and the holder of such position does not have any management role in the Group. The designation of the lead independent non-executive Director is introduced with reference to the amended Corporate Governance Code as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which became effective on July 1, 2025. As at the date of this announcement, the Board comprised Mr. WANG Legang as an executive Director; Ms. YANG Ling, Mr. LIN Jixun, Mr. LI Bo and Mr. ZHOU Mintao as non-executive Directors; and Mr. MI Brian Zihou, Mr. YEH Richard and Mr. ZHANG Wei as independent non-executive Directors. Announcement • Mar 26
Adicon Holdings Limited (SEHK:9860) acquired 10% stake in Astrabio. Adicon Holdings Limited (SEHK:9860) acquired 10% stake in Astrabio on August 23, 2025.
Adicon Holdings Limited (SEHK:9860) completed the acquisition of 10% stake in Astrabio on August 23, 2025. Announcement • Mar 25
Adicon Holdings Limited, Annual General Meeting, May 31, 2026 Adicon Holdings Limited, Annual General Meeting, May 31, 2026. Announcement • Mar 13
Adicon Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026 Adicon Holdings Limited announced that they will report fiscal year 2025 results on Mar 25, 2026 Announcement • Feb 13
Adicon Holdings Limited Announces Appointment of Wang Legang as Executive Director and Member of Strategy Committee, Effective February 13, 2026 Adicon Holdings Limited announced that with effect from February 13, 2026, Mr. WANG Legang has been appointed as an executive Director of the Company. Mr. WANG has been appointed as the chief operating officer and the general manager of the Group since August 15, 2025 and he will continue to act as the chief operating officer and the general manager of the Group. Mr. WANG, aged 45, has extensive experience in healthcare business management and digital transformation. Early in his career, from July 2004 to March 2009, Mr. WANG was a pharmaceutical engineer at Qingdao Huanghai Pharmaceutical Co. Ltd. From March 2009 to July 2014, Mr. WANG served as a regional manager and marketing manager at Pfizer (China) Investment Co. Ltd. He then served as a regional director responsible for pharmaceutical sales of Merck (China) Investment Co. Ltd. from July 2014 to March 2018, before becoming a vice president of the Medlinker, a role he held from March 2018 to February 2021 mainly in charge of the group’s business management and digital pharmaceutical sales networks development. From February 2021 to September 2024, he served as the senior vice president of Cowell Health and also led the interactive medicine and innovative drug division of the group as a general manager. From April 2025 to August 2025, Mr. WANG served as the deputy general manager of the Jointown Pharmaceutical Group and the general manager of Jiuyi Clinic (Hubei) Co. Ltd. Mr. WANG obtained a bachelor’s degree in clinical pharmacy from Harbin Medical University in the People’s Republic of China in June 2004 and finished EMBA courses from Ocean University of China in November 2014. A service agreement has been entered into between Mr. WANG and the Company for a term of three years commencing from his appointment. Mr. WANG’s appointment as an executive Director shall be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Company’s articles of association. With effect from February 13, 2026, Mr. WANG has been further appointed by the Board as a member of the strategy committee of the Board. Announcement • Nov 13
Adicon Holdings Limited (SEHK:9860) entered into a definitive agreement to acquire Crown Bioscience, Inc. from Crown Bioscience International. Adicon Holdings Limited (SEHK:9860) entered into a definitive agreement to acquire Crown Bioscience, Inc. from Crown Bioscience International on November 13, 2025. This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership. Crown Bioscience's Global Biospecimens business, headquartered in Hamburg, Germany, with facilities in Frederick, MD, will remain fully integrated within JSR Life Sciences.
The transaction is subject to customary closing conditions and is expected completion of the transaction is in 2026. Announcement • Aug 22
Adicon Holdings Limited Appoints Zhu Jonathan as Non-Executive Director and Member of the Strategy Committee of the Board, with Effect from August 22, 2025 The board of directors of ADICON Holdings Limited announced that: With effect from August 22, 2025, Mr. ZHU Jonathan ("Mr. ZHU") has been appointed as a non-executive Director and is responsible for providing professional opinion and judgment to the Board. The biographical details of Mr. ZHU are as follows: Mr. ZHU, aged 57, has extensive experience in the industrial and medical diagnostic industries. Early in his career, from 1992 to 1996, Mr. ZHU was with the US Air Force (USAF). From June 1996 to September 1998, he was the China general manager at Environmental Elements Corporation. He then served as a senior lobbyist at EOP Group Inc. in Washington, D.C. from June 2000 to June 2005, before becoming a corporate director at HORIBA Group, a role he held from June 2005 to January 2010. From September 2014 to October 2022, he led the APAC healthcare and life sciences practice as regional managing partner at Heidrick & Struggles. Since November 2022, Mr. ZHU has been the APAC managing partner of the life sciences practices at Korn Ferry (Sg) Pte Ltd. Mr. ZHU currently serves as a senior advisor to AdvaMed. His previous advisory appointments include senior advisor to The Carlyle Group (NASDAQ: CG) from 2019 to July 2025, and advisor to the chairman of Shenzhen Hepalink Pharmaceutical Co. Ltd. from 2020 to 2024, and member of the Asia advisory board of Coloplast from 2013 to 2021. Mr. ZHU obtained a bachelor's degree in engineering from University of Maryland in the United States in May 1992, an MBA from University of Baltimore in the United States in May 2000 and a master's degree in laws from China University of Political Science and Law in China in 2012. With effect from August 22, 2025, Mr. ZHU has been further appointed as a member of the strategy committee of the Board. Announcement • Aug 12
Adicon Holdings Limited to Report First Half, 2025 Results on Aug 22, 2025 Adicon Holdings Limited announced that they will report first half, 2025 results on Aug 22, 2025 Announcement • Mar 31
Adicon Holdings Limited, Annual General Meeting, May 31, 2025 Adicon Holdings Limited, Annual General Meeting, May 31, 2025. Announcement • Mar 20
Adicon Holdings Limited to Report Fiscal Year 2024 Results on Mar 31, 2025 Adicon Holdings Limited announced that they will report fiscal year 2024 results on Mar 31, 2025 Announcement • Aug 20
Adicon Holdings Limited to Report First Half, 2024 Results on Aug 30, 2024 Adicon Holdings Limited announced that they will report first half, 2024 results on Aug 30, 2024 Announcement • Jun 01
Adicon Holdings Limited Approves Appointment of Mr. Zhou Mintao as A Non-Executive Director Adicon Holdings Limited at the Annual General Meeting approved appointment of Mr. ZHOU Mintao as a non-executive director of the Company. executive Director has been approved by the Shareholders at the 2024 AGM. Mr. ZHOU has entered into a letter of appointment with the Company for a term of 3 years commencing from May 30, 2024 subject to the articles of association of the Company and the Listing Rules. Pursuant to the appointment letter entered into by Mr. ZHOU with the Company, he is entitled to receive a remuneration of RMB732,000 annually with discretionary bonus for his directorship with the Company with reference to his duties and responsibilities towards the Company and prevailing market conditions. Upon Mr. ZHOU's appointment as a non-executive Director, the Board has resolved to appoint Mr. ZHOU as the chairman of the strategy committee of the Board with effect from May 30, 2024 and accept the resignation of Ms. YANG Ling as the chairwoman of the Strategy Committee on the same date. Ms. YANG will continue to serve as a member of the Strategy Committee. Announcement • Mar 29
Adicon Holdings Limited, Annual General Meeting, May 31, 2024 Adicon Holdings Limited, Annual General Meeting, May 31, 2024. Announcement • Mar 20
Adicon Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Adicon Holdings Limited announced that they will report fiscal year 2023 results on Mar 28, 2024 
